Videos

With Eileen O’Reilly, MD, the Oncology Brothers discuss the essential steps in the initial workup for a newly diagnosed pancreatic cancer patient, including clinical evaluation, imaging, biopsy, and multidisciplinary staging for treatment planning.

Panelists discuss how prophylactic use of tocilizumab in the MajesTEC-1 trial may reduce the incidence and severity of cytokine release syndrome (CRS) in patients receiving bispecific antibody therapy for multiple myeloma, potentially improving treatment safety and tolerability.

The Together for Supportive Cancer Care coalition may advance the national conversation in ensuring comprehensive care for all patients with cancer.

Panelists discuss how the follow-up results from the RedirecTT-1 study provide insights into the long-term efficacy and safety of bispecific antibody combinations in treating relapsed/refractory multiple myeloma, potentially shaping future treatment approaches for this challenging disease.

Health care organizations have come together to form the Together for Supportive Cancer Care coalition to address gaps in supportive cancer care services.

Panelists discuss how results from the GALAXY study reveal that circulating tumor DNA (ctDNA) status is a powerful predictor of outcomes and treatment benefit in patients with colorectal cancer (CRC), potentially revolutionizing personalized treatment approaches.

Panelists discuss how the GALAXY study data demonstrate the effectiveness of circulating tumor DNA (ctDNA)–based minimal residual disease (MRD) monitoring in patients with resected colorectal cancer (CRC), potentially improving postsurgical care and outcomes.

Panelists discuss how patient-specific factors like age, comorbidities, cytogenetic risk status, and personal preferences guide decisions to deviate from standard protocols, with particular attention to frailty scores and organ function when considering treatment intensity.

Panelists discuss how the updated WHO classification system for gliomas has impacted their treatment approaches, while also addressing the practical difficulties of integrating these changes into routine clinical care.

Panelists discuss how a patient navigated her recurrent breast cancer diagnosis, detailing the symptoms, referral process, diagnostic tests, treatment considerations, and the concerns faced throughout the journey, while also examining the steps taken to confirm her HER2+ diagnosis.

Panelists provide a brief overview of breast cancer, discussing typical presentations of advanced breast cancer; key risk factors such as age, gender, and family history; various subtypes of the disease; and the essential steps in diagnosing, risk assessing, and staging patients.

Panelists discuss how the CARTITUDE-4 trial results show cilta-cel's superior efficacy over standard of care therapies in treating relapsed/refractory multiple myeloma, potentially reshaping treatment paradigms for this patient population.

Panelists discuss how the KarMMa-3 trial results demonstrate superior efficacy of ide-cel compared to standard of care therapies in patients with relapsed/refractory multiple myeloma, potentially establishing a new benchmark for treatment in this setting.

Further optimizing a PROTAC that targets MDM2 may lead to human clinical trials among patients with cancer harboring p53 mutations.

As patients are nearing the end of life, different management strategies, such as opioids, may be needed to help mitigate pain or fatigue.

Kelley A. Rone, DNP, RN, AGNP-c, highlights the importance of having end-of-life discussions early in a patient’s cancer treatment course.

Patients treated with BCMA-directed immunotherapies for myeloma may experience susceptibility to severe infections following treatment.

Panelists discuss how referral types for multiple myeloma patients vary widely, including newly diagnosed cases, relapsed/refractory disease, and specific therapy considerations like bispecifics, with processes differing between in-state and out-of-state referrals due to logistical and insurance factors.

Panelists discuss how the use of GPRC5D-targeted therapies impacts healthcare resource utilization in the community setting, including potential changes in hospitalizations, outpatient visits, and supportive care needs.

Panelists discuss how the evaluation and treatment initiation processes for non-BCMA targeted bispecifics and BCMA-targeted bispecifics share core similarities in patient assessment and care coordination, but differ in specific premedication protocols, dosing strategies, and side effect management.

Panelists discuss the rationale behind combination strategies with bispecifics in relapsed/refractory multiple myeloma (R/R MM), highlighting key studies such as RedirecTT-1 for teclistamab and talquetamab, TRIMM-2 for talquetamab and daratumumab, and MagnetisMM-32 for elranatamab, along with considerations for step-up dosing and outpatient administration protocols.

Panelists discuss how data from the long-term update from CARTITUDE-4 reveal impressive overall response rates (ORRs) and duration of response (DOR) for ciltacabtagene autoleucel, reinforcing its effectiveness in treating lenalidomide-refractory multiple myeloma.

Panelists discuss how logistical barriers like drug access, insurance coverage, and managing infusion logistics have posed challenges in the implementation of GPRC5D-targeted therapies in community practice.

Experts on multiple myeloma outline current challenges in determining the optimal treatment strategy for patients with relapsed/refractory disease who are eligible for bispecifics and CAR T-cell therapy.

The panel concludes its discussion with key takeaways on unmet needs and evolving treatment paradigms in relapsed/refractory multiple myeloma.

BCMA testing tracks clinical changes faster without the need for marker expression vs monoclonal immunoglobulin, a conventional multiple myeloma marker.

Studies indicate that higher BCMA levels are associated with a greater need for therapy years following diagnosis for patients with smoldering myeloma.

With Martina Murphy, MD, collaborates with the Oncology Brothers to explore personalized treatment strategies for ovarian cancer, emphasizing dose reduction and the management of adverse effects to enhance patient care and outcomes.

With Martina Murphy, MD, the Oncology Brothers discuss maneuvering through different treatment options for ovarian cancer, emphasizing the need for personalized approaches to optimize patient care and outcomes.

With Martina Murphy, MD, the Oncology Brothers discuss maintenance therapies in ovarian cancer, focusing on their potential to prolong progression-free survival and improve quality of life for patients.